Skip to content
value.today

Lunai Bioworks Inc.

LNAI
$1 Mmarket cap on Oct 28, 2026
Compare
World rank
#27,958
Revenue
$0 M
For year ending June-2026
Net income
$-4 M
-7120.0% margin
SEC filing
Employees
12
As of June 30, 2026
SEC filing

Lunai Bioworks Inc. in brief

Lunai Bioworks Inc. is a listed company in the Biotechnology industry, based in Suite 906 Los Angeles, California, USA. Its market value was $1 M on 28 October 2026, which makes it the 27,958th largest listed company in the world and the 4,514th largest in the USA on this site. In the year to June 2026 it had sales of $0 M and a net loss of $4 M. It employs about 12 people. Its shares trade under the symbol LNAI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lunai Bioworks Inc.

As of June 30, 2026, Lunai Bioworks Inc. operated principally through two operating subsidiaries, Renovaro Biosciences and BioSymetrics; a third wholly owned subsidiary, Lunai Bioworks IP, Inc., holds the intellectual property acquired in the May 2026 Neurobridge acquisition, including the N2B intranasal drug delivery platform. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025.

During the quarter ended September 30, 2025, GEDi Cube B.V., acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and subsequent deconsolidation, the Company continued pursuing its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics, which had been acquired prior to the bankruptcy. BioSymetrics' existing AI and machine-learning platform provided capabilities that overlapped with GEDi Cube's cancer diagnostics and biomarker discovery objectives while supporting a broader range of applications, including therapeutic development, central nervous system disorders, and biodefense. Using its independently developed technology, BioSymetrics continued pursuing cancer-related diagnostic and biomarker opportunities while expanding the Company's research and business development activities into additional therapeutic areas. Accordingly, GEDi Cube's bankruptcy did not represent a change in the Company's overall strategic direction, as its AI-driven biomedical research and development strategy continued and expanded through BioSymetrics. Following GEDi Cube's deconsolidation, the Company's consolidated operations consisted principally of Renovaro Biosciences' cell and gene therapy programs and BioSymetrics' AI-driven biotechnology platform.

From the company's annual report filed with the US SEC: read the report

Lunai Bioworks Inc. timeline

6 events, 2011–2025
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. ✎
    Renamed DanDrit Biotech USA, Inc.
    Formerly Putnam Hills Corp..
  5. 2018
  6. ✎
    Renamed Enochian Biosciences Inc
    Formerly DanDrit Biotech USA, Inc..
  7. 2023
  8. ✎
    Renamed Renovaro Biosciences Inc.
    Formerly Enochian Biosciences Inc.
  9. 2024
  10. ✎
    Renamed Renovaro Inc.
    Formerly Renovaro Biosciences Inc..
  11. 2025
  12. ✎
    Renamed Lunai Bioworks Inc.
    Formerly Renovaro Inc..

Events of Lunai Bioworks Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1 M$3 M$4 M$6 M

World rank over time

▼ down 1,125 places since 2026
2026-10-14: #26839#26,83920262026-10-28: #27964#27,9642026

Rank in USA: #4,348 (Oct 2026) · #4,517 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
25.2×
Price / book
—
Free cash flow yield
-419.8%
Net margin (TTM)
-7120.0%
Operating margin
-17400.0%
Return on equity
—
Liabilities / assets
190.8%
Revenue growth
+25.0%
R&D / revenue
40.0%
Revenue per employee
$4 K
Profit per employee
$-297 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2019: revenue —, net income $-18M—FY19Fiscal year ending Jun 2020: revenue —, net income $-11M—FY20Fiscal year ending Jun 2021: revenue —, net income $-27M—FY21Fiscal year ending Jun 2022: revenue —, net income $-113M—FY22Fiscal year ending Jun 2023: revenue —, net income $-40M—FY23Fiscal year ending Jun 2024: revenue —, net income $-88M—FY24Fiscal year ending Jun 2025: revenue —, net income $-178M—FY25Fiscal year ending Jun 2026: revenue $0M, net income $-4M$0MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2026$0M—$-9M$-4M-7120.0%
Jun 2025——$-189M$-178M—
Jun 2024——$-82M$-88M—
Jun 2023——$-39M$-40M—
Jun 2022——$-116M$-113M—
Jun 2021——$-23M$-27M—
Jun 2020——$-12M$-11M—
Jun 2019——$-11M$-18M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2026$-5M$0M$-5M$-1.06—
Jun 2025$-8M——$-86.27—
Jun 2024$-11M$0M$-11M$-0.91—
Jun 2023$-12M$0M$-12M$-0.71—
Jun 2022$-16M$0M$-16M$-2.16—
Jun 2021$-21M$0M$-21M$-0.57—
Jun 2020$-10M$0M$-11M$-0.25—
Jun 2019$-9M$1M$-9M$-0.48—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-4M
RevenueNet income
Three months to Sep 2024: revenue —, net income $-44M—Sep ’24Three months to Dec 2024: revenue —, net income $-7M—Dec ’24Three months to Mar 2025: revenue —, net income $0M—Mar ’25Three months to Jun 2025 (from the annual report): revenue —, net income $-127M—Jun ’25Three months to Sep 2025: revenue —, net income $3M—Sep ’25Three months to Dec 2025: revenue —, net income $-2M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-3M$0MMar ’26Three months to Jun 2026 (from the annual report): revenue —, net income $-2M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Lunai Bioworks Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-9 M
Net income
$-4 M

For year ending June-2026 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$19 M
Total equity
$-9 M

As of June-2026

Top 17 institutional investors in Lunai Bioworks Inc.#

As of Sep 30, 2026
17 institutions held 190,863 shares (about 3.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 3.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 17 largest institutional investors in Lunai Bioworks Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC49,977+33,896 (+210.78%)0.99%$0 MNov 13, 2026
2Geode Capital Management, LLC41,514+17,358 (+71.86%)0.82%$0 MNov 6, 2026
3State Street Corp37,5370 (0.00%)0.75%$0 MNov 12, 2026
4Jane Street Group, LLC21,635-2,048 (-8.65%)0.43%$0 MNov 12, 2026
5BlackRock, Inc.15,9060 (0.00%)0.32%$0 MNov 13, 2026
6UBS Group AG12,234New0.24%$0 MNov 10, 2026
7Vanguard Fiduciary Trust Co8,6420 (0.00%)0.17%$0 MNov 13, 2026
8Tower Research Capital LLC (TRC)3,035+1,630 (+116.01%)0.06%$0 MNov 16, 2026
9Morgan Stanley3260 (0.00%)0.01%$0 MNov 13, 2026
10BNP Paribas Financial Markets240 (0.00%)0.00%$0 MNov 12, 2026
11Jacobi Capital Management LLC10New0.00%$0 MNov 5, 2026
12Jpmorgan Chase & Co60 (0.00%)0.00%$0 MNov 12, 2026
13Caitong International Asset Management Co., Ltd6New0.00%$0 MOct 29, 2026
14Royal Bank Of Canada5-1,682 (-99.70%)0.00%$0 MNov 16, 2026
15Barclays PLC4New0.00%$0 MNov 6, 2026
16Group One Trading LLC1-543 (-99.82%)0.00%$0 MNov 10, 2026
17Deutsche Bank AG\10 (0.00%)0.00%$0 MNov 6, 2026

Mutual funds holding Lunai Bioworks Inc.#

6 funds hold shares worth $0 M (about 0.6% of the company). Since their previous reports 2 added shares and 6 sold, selling $0 M net.
Mutual funds holding Lunai Bioworks Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC13,363$0 M0.27%<0.01%+43%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.12,063$0 M0.24%<0.01%+0.0%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC1,898$0 M0.04%<0.01%−0.0%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,754$0 M0.03%<0.01%−0.0%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC1,157$0 M0.02%<0.01%−0.0%May 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC23$0 M<0.01%<0.01%−76%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lunai Bioworks Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
16
since
-$514 K$0Jun 2024: bought $0 (0 trades), sold $211 K (4 trades)Jun 24Jul 2024: bought $0 (0 trades), sold $514 K (10 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Lunai Bioworks Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Anderson Wittekind William10% ownerOther-350,000——3.35 MForm 4
filed Maurice Van TilburgDirectorGrant or award+250,000——250,000Form 4
filed David Hershel WeinsteinChief Executive Officer, DirectorGrant or award+250,000——250,000Form 4
filed Avram MillerDirectorDisposal to the company-833,333——166,667Form 4
filed Karen BrinkDirector, 10% ownerOtherindirect · amended+2.00 M——25.37 MForm 4/A
filed Karen BrinkDirector, 10% ownerOtherindirect-2.00 M——23.37 MForm 4
filed Anderson Wittekind William10% ownerSellindirect-1,114$1.300$1 K840,319Form 4
filed Anderson Wittekind William10% ownerSellindirect-16,362$1.460$24 K841,433Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lunai Bioworks Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
19,381
0.4% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-10-09 18:06 UTC, code LUDP, resumed 18:16 UTC
  • 2026-05-21 23:50 UTC, code T3, resumed 13:00 UTC
  • 2026-03-26 13:37 UTC, code LUDP, resumed 13:42 UTC

Fails to deliver

  • : 3,202 shares at $0.25
  • : 118,293 shares at $0.29
  • : 5,011 shares at $0.47
  • : 471 shares at $0.52
  • : 425 shares at $0.47

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lunai Bioworks Inc. scorecard#

Passes 1 of the 13 checks that could be worked out. Fiscal year 2026; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median25.2×Price to sales 25.2× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.06 vs -86.27Diluted EPS -1.06 in fiscal 2026 against -86.27 the year before (report's currency).
    • ✓Net income higher than five years earlier-$4 M-$4 M in fiscal 2026 against -$27 M in 2021.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$4 MNet income -$4 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 4
    • ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.11 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-36.2×Operating income -36.2 times interest in fiscal 2026.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
    • ✗Altman Z-score outside the distress zone-77.28Z-score -77.28 (distress zone) for fiscal 2026.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year62.9%Diluted shares up 62.9% in fiscal 2026.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Lunai Bioworks Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lunai Bioworks Inc.: statements by fiscal year
PeriodTrendFY 2026to Jun 30, 2026FY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017
Income statement
Revenue0.1—————————
Research and development0.00.52.74.28.416r4.72.50.60.1
General and administrative7.8182515147.6r7.18.4r3.9r0.9r
Operating expenses8.718982391162312115.3r2.4r
Operating income−8.7−189−82−39−116−23−12−11−5.3r−2.4r
Interest and finance income————0.10.00.10.10.0—
Interest expense and finance costs0.20.71.00.60.40.40.10.00.1—
Net interest income———−0.10.1—————
Other non-operating income (expense)5.111−6.8r−1.12.6−3.40.5−7.0−1.10.2
Income before tax———−40−113−27−11−18−6.4r−2.2r
Income tax0.00.00—0.0−0.1——−0.1−0.1
Net income including minority interests−3.6−178−88r−40————−9.2−2.5
Net income attributable to shareholders−3.6−178−88r−40−113−27−11−18−6.3r−2.1r
Earnings per share, basic-1.06-86.27r-0.91r-0.71-2.16-0.57-0.25-0.48-0.29r-0.17r
Earnings per share, diluted-1.06-86.27r-0.91r-0.71-2.16-0.57-0.25-0.48-0.29r-0.17r
Shares, weighted average (basic)3.42.1r98r5653————12
Shares, weighted average (diluted)3.42.1r98r56534746382212
Balance sheet
Cash and cash equivalents1.70.10.21.99.2218.712163.9
Other current assets——0.7—0.4—————
Current assets2.01.02.02.69.6218.912164.2
Property, plant and equipment0.00.40.50.50.60.70.80.70.0—
Right-of-use (leased) assets—0.71.30.91.21.41.7———
Goodwill6.06.0159121212121212—
Other intangible assets1.40.20.00.00.00.10.10.1148r0.1
Non-current assets——————168167167r0.3
Total assets9.98.21635885190178180183r4.5
Accounts payable12139.45.31.40.30.60.50.60.4
Current liabilities192930116.51.91.31.10.93.0
Lease liabilities (non-current)0.10.40.80.81.01.21.5———
Non-current liabilities0.10.40.80.85.613r12———
Total liabilities193031121215126.8243.0
Retained earnings−514−510−332r−244−204−91−64−53−35r−28r
Shareholders' equity−9.0−211324773175166173159r1.5
Total equity——13247——————
Total liabilities and equity9.98.21635885190178180183r4.5
Shares outstanding4.62.2r158r64535246453612
Cash-flow statement
Depreciation and amortization0.10.10.10.10.10.10.10.10.0r0.0
Share-based compensation0.63.34.73.55.21.30.92.10.1r0.6
Cash from operating activities−5.3−7.9−11−12−16−21−10−8.5−4.3−1.2
Capital expenditure−0.0—−0.1−0.0−0.0−0.0−0.2−0.7−0.0—
Acquisitions, net of cash acquired————————−0.3—
Cash from investing activities0.5−0.5−1.3−0.0−0.0−0.0−0.2−0.7−0.6−0.2
Debt issued5.003.80——————
Shares issued—————0.1——173.5
Cash from financing activities6.48.4114.54.3337.26.0175.5
Exchange-rate effect on cash−0.0−0.10.1−0.0−0.00.0−0.1−0.1−0.1−0.2
Change in cash1.6−0.1−1.7−7.3−1112−3.6−3.3123.9
Report10-K10-K10-K10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Lunai Bioworks Inc. operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.

Lunai Bioworks Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office3 subsidiaries—
🇩🇰 Denmark1 subsidiary—
🇳🇱 Netherlands1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Lunai Bioworks Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

And 5 more in the list below.

Delisting notice 10 · Impairment 1 · Taken over and delisted 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 5 · Unregistered share sale 5 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 2

Lunai Bioworks Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Delisting noticeDirectors and officers8-K
Shareholder vote8-K
Delisting notice8-K/A
Taken over and delistedAcquisition or sale completedMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Delisting notice8-K
Material agreement8-K
Unregistered share sale8-K
Delisting notice8-K
Shareholder vote8-K
Delisting notice8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Impairment8-K
Bylaws or fiscal year changed8-K
Delisting notice8-K
Directors and officers8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Delisting notice8-K
Unregistered share sale8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Lunai Bioworks Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2024$107 MPrivate placement after listing$50 to $250 million8equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Lunai Bioworks Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2026, most often on defense.

Lobbying, 2026
$20 K
#1,440 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2026
2026 so far
$20 K
  • Defense3 reports

Lobbying firms hired in 2026

American Defense International, Inc. $20 K

Lunai Bioworks Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$20 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Lunai Bioworks, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Lunai Bioworks Inc. compares in Biotechnology

  • Market cap$1 M · higher than 1% of 726
  • Revenue$0 M · higher than 15% of 647
  • Price / sales25.2× · lower than 27% of 339

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Lunai Bioworks Inc.🇺🇸$1 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending June-2026
Balance sheet:
As of June-2026
Employees:
As of June 30, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lunai Bioworks Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lunai Bioworks Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lunai Bioworks Inc.? Suggest a correction